Current WHO GUIDE for Rabies Pre and Post-exposure Prophylaxis in Humans
(revised December 2007)
General considerations in rabies Post-Exposure Prophylaxis (PEP)

WHO strongly advocates the use of modern (purified products prepared on cell-culture) vaccines for PEP that comply with WHO criteria for potency, innocuity and have been assessed satisfactorily in humans in well-designed field trials;

WHO supports the trend to abandon completely the production and use of brain-tissue vaccines.
General considerations in rabies PEP

Immediate washing/flushing and disinfection of the wound plus rapid administration of purified immunoglobulin and modern vaccine according to the modalities described in these guidelines assure prevention of infection in almost all circumstances.

Rabies PEP

– is an emergency and as a general rule should not be delayed or deferred;
– does not have contraindications if modern purified rabies biologicals are used;
– must be applied using vaccine regimens and routes of administration that have been proven to be safe and effective.
General considerations in rabies PEP

Rabies PEP is an emergency!

– wounds should be washed/flushed and disinfected immediately. Vaccine and serum therapy (when required for the latter) instituted as soon as possible,

– initiation of PEP should not await the results of laboratory diagnosis or be delayed by dog observation when rabies is suspected,

– pregnancy and infancy are never contraindications to PEP,

– persons who present for evaluation and rabies post-exposure prophylaxis even months after having been bitten should be dealt with in the same manner as if the contact occurred recently.
General considerations in PEP

Deferring PEP:

an exception in rabies endemic countries or areas!

- If the species is unlikely to be infected with rabies, wait for laboratory diagnosis if results can be obtained within 48 hours;

- If the dog at the origin of exposure is more than a year old and has a vaccination certificate indicating that it has received at least 2 doses of a potent vaccine, the first not earlier than 3 months of age and another within 6 to 12 months later, observe the dog 10 days. If the dog has been immunized during a mass vaccination campaign PEP should not be withheld.

- If the dog shows any sign of illness during the observation period, the patient should receive full rabies post-exposure prophylaxis urgently.
Rabies post-exposure Prophylaxis modalities

Wound treatment:

- should be immediate
- is essential even if the person presents long after exposure
- consists of:
  - immediate washing and flushing for 15 minutes with soap and water, or water alone,
  - disinfection with ethanol (700ml/l) or iodine (tincture or aqueous solution).
Rabies PEP modalities

Definition of categories of exposure and use of rabies biologicals:

**Category I:** - touching, feeding of animals or licks on intact skin

*no exposure therefore no prophylaxis if history reliable*

**Category II:** - minor scratches or abrasions without bleeding or licks on broken skin and nibbling of uncovered skin

*use vaccine alone*

**Category III:** - single or multiple transdermal bites, scratches or contamination of mucous membrane with saliva (i.e. licks) and suspect contacts with bats:

*use immunoglobulin plus vaccine*
Rabies PEP modalities

Administration of rabies immunoglobulin (RIG)

- Infiltrate into the depth of the wound and around the wound
  - as much as anatomically feasible of the RIG should be infiltrated around the wound
  - any remainder should be injected at an intramuscular site distant from that of vaccine inoculation e.g. into the anterior thigh

- Quantities/volume of RIG: 20IU/ kg for Human RIG or 40 IU/ kg of Equine RIG
  - the total recommended dose should not be exceeded
  - if the calculated dose is insufficient to infiltrate all wounds, sterile saline may be used to dilute it 2 to 3 fold to permit thorough infiltration
Rabies PEP modalities

Non-specific care

- Postpone suturing if possible; if suturing is necessary ensure that RIG has been applied locally;

- Apply antimicrobials and tetanus toxoid if necessary
Rabies PEP intramuscular regimens

Two intramuscular schedules for modern vaccines:

- Vaccines should not be injected into the gluteal region;

- Classical 5 dose intramuscular regime (“Essen” regimen): one dose of the vaccine should be administered on days 0, 3, 7, 14 and 28 in deltoid region or, in small children, into the antero-lateral area of the thigh muscle;

- As an alternative, the 2-1-1 regimen may be used. Two doses are given on day 0 in the deltoid muscle, right and left arm. In addition one dose in the deltoid muscle on day 7 and one on day 21.
General considerations on intradermal PEP

- As these regimens require considerably less vaccine than the intramuscular regimens the method is particularly appropriate where vaccine or money is in short supply;

Intradermal injections reduce the volume of vaccine required and vaccine cost by 60% to 80%
The decision to implement economical intradermal post-exposure prophylaxis rests with government agencies that define rabies prevention and prophylaxis policies in their own countries.

When the intradermal route is used, precautions include staff training, conditions and duration of vaccine storage after reconstitution, use of appropriate 1 mL syringe and short hypodermic needles.
General considerations on intradermal PEP against rabies

Three vaccines have proven to be efficacious

- Human diploid cell vaccine (HDCV) Rabivac™
- Purified vero cell vaccine (PVRV) Verorab™,
- Purified chick embryo cell vaccine (PCECV) Rabipur™
General considerations on intradermal PEP against rabies

Recommended intradermal regimens and vaccines for use by the intradermal route

- 8-site intradermal method (8-0-4-0-1-1) for use with HDC (Rabivac™) and PCECV (Rabipur™)
- 2-site intradermal method (2-2-2-0-2) for use with PVRV (Verorab™) and PCECV (Rabipur™).
Intradermal PEP regimens for modern rabies vaccines

2-site intradermal method ('2-2-2-0-2' )

The volume per intradermal site is:

- 0.1 mL for PVRV (Verorab™) and PCECV (Rabipur™)
- one dose of vaccine, in a volume of 0.1 ml is given intradermally at two different lymphatic drainage sites, usually the left and right upper arm, on days 0, 3, 7 and 28. Vaccine administered intradermally must raise a visible and palpable “bleb” in the skin. In the event that a dose of vaccine is inadvertently given subcutaneously or intramuscularly, a new dose should administered intradermally.
Intradermal PEP regimens for modern rabies vaccines

8-site intradermal method ('8-0-4-0-1-1')

for use with

- human diploid cell vaccine (HDCV) (Rabivac™) and
- purified chick embryo cell vaccine (PCECV) (Rabipur™)

both vaccines at 0.1 mL per intradermal site

- One dose of 0.1 mL is administered intradermally at eight different sites (upper arms, lateral thighs, suprascapular region, and lower quadrant of abdomen) on day 0. On day 7, four 0.1 mL injections are administered intradermally into each upper arm (deltoid region) and each lateral thigh. Following these injections, one additional 0.1 mL dose is administered on days 28 and 90.
Intradermal route and rabies vaccine potency requirements

- The antigenic potency of all the WHO approved vaccines has proven similar and is well above the minimum value of 2.5 IU/ampoule;

- WHO minimum potency requirement for human rabies vaccines for intradermal use should not be increased beyond 2.5 IU (per single intramuscular dose) by national authorities unless the need for a change is substantiated by clinical or field studies;
To be approved for id use, any new candidate vaccine should be proven potent by the NIH test and its immunogenicity and safety should be demonstrated with the volume intended for humans;

Any country willing to adopt an id regimen of proven efficacy with the recommended vaccines need not repeat immunogenicity studies in their own population.
Vaccine vial insert for intradermal use of rabies vaccines for PEP

For vaccines recommended by WHO to be used intradermally, the vaccine insert should contain a statement saying:

“This vaccine is of sufficient potency to allow its safe use in one of the WHO recommended intradermal post-exposure regimens in countries where relevant national authorities have approved the intradermal route for rabies PEP”.

(revised 30 June 2009)
Rabies PEP in immunosuppressed individuals

- The importance of wound treatment should be further stressed;
- RIG should be administered deeply into the wound for all exposures;
- Vaccine should always be administered and no modification of the recommended number of doses is advisable;
- An infectious disease specialist with expert knowledge of rabies prevention should be consulted.
Interchangeability of modern rabies vaccine types and routes for PEP

- Interchangeability of modern rabies vaccine is not recommended;
- When completion of PEP with the same modern rabies vaccine is not possible, the switch can be done provided that it is one of the WHO recommended cell culture vaccine;
- No study has been done yet on vaccine immunogenicity and change of the route of vaccine administration (e.g. from intramuscular to intradermal) during PEP. This practice should be the exception.
Rabies PEP of previously vaccinated persons

- Local treatment of wound
- Vaccination schedule (with vaccines fulfilling WHO requirements)
  - one dose on days 0 and 3. The dose is either 1 standard intramuscular dose (which may be 1 ml or 0.5 ml depending on vaccine type) or one intradermal dose of 0.1 ml per site
  - no RIG should be applied

  However full PEP should be given to persons:
  - who received pre- or post-exposure prophylaxis with vaccines of unproven potency or
  - in patients in whom immunological memory is not longer assured as a result of HIV/AIDS or other immunosuppressive causes
Pre-exposure rabies vaccination

- Groups of persons at high risk of exposure to live rabies virus (laboratory staff, veterinarians, animal handlers and wildlife officers)
- Toddlers and children in highly endemic areas may be considered if vaccine quantities for PEP are adequate
- Regimen (with vaccines fulfilling WHO requirements)
  - three doses of vaccine on days 0, 7 and 28
  - A dose is either 1 standard intramuscular dose (0.5 or 1 mL) or 0.1mL intradermally (if antimalarial chemoprophylaxis is applied concurrently, intramuscular injections are preferable to intradermal)
  - Alternative regimens are being tested for preventive vaccination of toddlers and children in highly endemic areas
- Site of injection (never use gluteal area for vaccine application)
  - adults: deltoid area of the arm;
  - children: anterolateral area of the thigh acceptable
Pre-exposure rabies vaccination

Monitoring

- Persons working with live rabies virus in
  - diagnostic laboratories
  - research laboratories
  - vaccine production laboratories
  - one serum sample every six months
  - booster when the titre falls below 0.5 IU/ml

- Others professions (veterinarians, animal handlers, wildlife officers...) at permanent risk of exposure to rabies
  - testing every year
  - booster when the titre falls below 0.5 IU/ml